About The Rx Consultant

The Rx Consultant is a subscription-based service that delivers practical updates & reviews covering all the top-selling drugs and common health conditions. Our publications focus on the facts busy front-line pharmacists and other health care practitioners need to stay current, and provide it a streamlined, easy reading style.

Founded in 1991, The Rx Consultant has subscribers throughout the United States, Canada & The United Kingdom. For 27 years, pharmacists, nurse practitioners and pharmacy technicians have relied on The Rx Consultant for accurate, unbiased updates they can trust. We are completely independent of the pharmaceutical industry and has no commercial bias.

→ Visit The Rx Consultant

Rx Blog users - Save 40% on a subscription to
The Rx Consultant

Use Promo Code RXBLOG18

→ Subscribe Now

Migraines affect 10% of the population - with women affected 3 times more than men. A first in class biologic, erenumab (Aimovig®), has been approved for migraine prevention. Erenumab is a monoclonal antibiody that binds to and blocks calcitonin gene-related receptors. In patients with episodic migraines (4 to 14 monthly), erenumab reduced migraine frequency by 1 to 2 days per month after 3 to 6 months of treatment. Patients with chronic migraines (at least 15 headaches and 8 migraines monthly) experienced an average of 2.5 fewer migraine days per month after 3 months of treatment.

Erenumab is self-injected subcutaneously (70 or 140 mg) once monthly. The most common side effects are injection site reaction (5-6%) and constipation (1-3%). The needle cover of the syringe and autoinjector contain latex, which may cause a reaction in latex-sensitive patients.

• FDA News Release; published online May 2018.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Share This